Three groups:
RA patients: 30 starting on Methotrexate, 30 starting on combination of Methotrexate and TNFalpha inhibitor.
PSA patients: 20 starting on Methotrexate, 20 starting on combination of Methotrexate and TNFalpha inhibitor.
AS patients: 20 starting on TNFalpha inhibitor
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00902005?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
